Skip to main content
SpringerLink
Log in

Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Prostaglandin D2 (PGD2) is lethal to murine and human melanoma cells at high doses, but synchronizes cells at G1 at non-toxic doses (2.5 or 5 μg/ml). We tested the lethality to B16 mouse melanoma cells of combinations of PGD2 with anticancer drugs. The drugs selected were mostly those used in treating human melanoma: actinomycin D, Bleomycin, BCNU, cis-platin, melphalan, 5-fluorouracil, and 1-β-D-arabinofuranosylcytosine (ara-C). PGD2 was combined with the drugs according to 3 different protocols:

Protocol 1

An asynchronous culture was given a long term (24 hr) exposure simultaneously to PGD2 + drug. Combinations with Bleomycin, ara-C or melphalan were additive or slightly antagonistic whereas PGD2 plus actinomycin D was significantly antagonistic.

Protocol 2

Cells synchronized in G1 by 24 hr PGD2 exposure were then given a short-term (2 hr) treatment with PGD2 + drug. Combinations with cis-platin, Bleomycin, BCNU or 5-fluorouracil were additive or slightly antagonistic, whereas melphalan and actinomycin D combinations were significantly antagonistic.

Protocol 3

Cells were released from a PGD2-induced G1 block and were exposed to drug at different times during cell progression. Actinomycin D was antagonistic when added immediately after release from the G1 block, but was significantly synergistic when added 10 to 12 hr later.

The effect of the combinations cannot be explained by available cell cycle or biochemical information. The antagonism between PGD2 and several of the drugs resembles the “cytoprotective” effect of PGD2 towards various noxious agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Santoro MG, Philpott GW, Jaffe BM: Inhibition of B16 melanoma growth in vivo by a synthetic analog of prostaglandin E2 Cancer Res 37:3774–3779, 1977

    Google Scholar 

  2. Bregman MD, Sander D, Meyskens Jr FL: Prostaglandins A1 and E1 inhibit the plating efficiency and proliferation of murine melanoma cells (Cloudman S-91) in soft agar. Biochem Biophys Res Commun 104:1080–1086, 1982

    Google Scholar 

  3. Honn KV, Romine M, Skoff A: Prostaglandin analogs as inhibitors of tumor cell DNA synthesis. Proc Soc Exp Biol Med 166:562–567, 1981

    Google Scholar 

  4. Bregman MD, Meyskens Jr FL: Inhibition of human malignant melanoma colony-forming cells in vitro by prostaglandin A1. Cancer Res 43:1642–1645, 1983

    Google Scholar 

  5. VonHoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF: Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926–1931, 1983

    Google Scholar 

  6. Bhuyan BK, Adams EG, Li LH, Timmins L, Badiner GJ, Barden K: Cytotoxicity and cell cycle effects of prostaglandins (PGs) on human and murine melanoma cells. Cancer Res 46:1688–1693, 1986

    Google Scholar 

  7. Wiley HM, Feingold KR, Wu J: Control of lymphoma cell growth by prostaglandins. (Abstract) Clinical Res 31:69A, 1983

    Google Scholar 

  8. Hughes-Fulford M, Wu J, Fukushima M: Control of cell cycle by PGJ2: a potential new class of anti-neoplastic agents. In: Bailey JM (ed) Symposium on prostaglandins and leukotrienes, Washington, 1984, pp. 128

  9. Fukushima M, Kato T, Ueda R, Ota K, Narumiya S, Hayaishi O: Prostaglandin D2, a potential antineoplastic agent. Biochem Biophys Res Commun 105:956–964, 1982

    Google Scholar 

  10. Sakai T, Yamaguchi N, Kawai K, Nishino H, Iwashima A: Prostaglandin D1 inhibits the proliferation of human malignant tumor cells. Prostaglandins 27:17–26, 1984

    Google Scholar 

  11. Fukushima M, Kato T, Ota K: In vivo activity of the antineoplastic prostaglandin. (Abstract) Proc Amer Assoc Cancer Res 25:350, 1984

    Google Scholar 

  12. Fitzpatrick FA, Stringfellow DA: Prostaglandin formation by malignant melanoma cells correlates inversely with cellular metastasis potential. Proc Natl Acad Sci(USA) 76:1765–1769, 1979

    Google Scholar 

  13. Bhuyan BK, Blowers CL, Crampton SL, Shugars KD: Cell-kill kinetics of several nogalamycin analogs and Adriamycin for Chinese hamster ovary, L1210 leukemia and B16 melanoma cells in culture. Cancer Res 41:18–24, 1981

    Google Scholar 

  14. Valeriotte F, Lin H: Synergistic interaction of anticancer agents. A cellular perspective. Cancer Treat Rep 59:895–899, 1975

    Google Scholar 

  15. Adams EG, Crampton SL, Bhuyan BK: Effect of 7-con-O-methylnogarol on DNA synthesis, survival and cell cycle progression of Chinese hamster ovary cells. Cancer Res 41:4981–4987, 1981

    Google Scholar 

  16. Bhuyan BK, Scheidt LG, Fraser TJ: Cell cycle phase specificity of antitumor agents. Cancer Res 32:398–407, 1972.

    Google Scholar 

  17. Madoc-Jones H, Mauro F: Site of action of cytotoxic agents in the cell life cycle. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Vol. 1, Springer-Verlag, Heidelberg, 1974, pp. 205–219

    Google Scholar 

  18. Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforsch 3:285–320, 1953

    Google Scholar 

  19. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regulation 22:27, 1984

    Google Scholar 

  20. Bregman MD, Peters E, Sander D, Meyskens FL: Dexamethasone, prostaglandin A1 and retinoic acid modulation of murine and human melanoma cells grown in soft agar. J Natl Cancer Inst 71:927–932, 1983

    Google Scholar 

  21. Kushima M, Kato T, Ota K, Kikuchi H, Yamada Y, Kitagawa I: Antitumor activities of marine prostanoids, Clavulone (Claviridenone) — comparison with antineoplastic prostaglandins. (Abstract) Proc Jap Cancer Assoc 42:243, 1983

    Google Scholar 

  22. Wiley MH, Feingold KR, Grunfeld C, Quesney-Haneeus V, Wu JM: Evidence for c-AMP-independent inhibition of S-phase DNA synthesis by prostaglandins. J Biol Chem 258:491–496, 1983

    Google Scholar 

  23. Robert A, Nezamis JE, Lancaster C, Hanchar AJ: Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, Hypertonic NaCl and thermal injury. Gastroenterology 77:433–443, 1979

    Google Scholar 

  24. Raskin DJ, Gray K: Cytoprotection of the urinary bladder with 16, 16-dimethyl prostaglandin E2 during cyclophosphamide therapy. (Abstract) Proc Amer Assoc Cancer Res 25:351, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer and Viral Diseases Research, The Upjohn Company, 49001, Kalamazoo, MI, USA

    Bijoy K. Bhuyan, Gloria J. Badiner, Earl G. Adams & Robin Chase

Authors
  1. Bijoy K. Bhuyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gloria J. Badiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Earl G. Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robin Chase
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhuyan, B.K., Badiner, G.J., Adams, E.G. et al. Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture. Invest New Drugs 4, 315–323 (1986). https://doi.org/10.1007/BF00173504

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173504

Key words

Search

Navigation